Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.66 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14578751 | 0.90 | POLB (0.85) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL517697 | 0.86 | HDAC3 (0.86) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL8361539 | 0.84 | TP53 (0.75) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL6003020 | 0.84 | POLB (0.70) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL2093671 | 0.83 | POLB (0.76) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL8141144 | 0.83 | POLB (1.00) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL6660579 | 0.82 | POLB (0.68) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL16438781 | 0.82 | POLB (0.68) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL3031716 | 0.82 | POLB (0.68) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL1107145 | 0.82 | MAPT (0.74) | POLBHDAC3HDAC1HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109883-A1 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2022203930-A9 | FLUOROGENIC CYANINE CARBAMATES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20210070690-A1 | CATALYST FOR CONVERTING ESTER TO AMIDE USING HYDROXYL GROUP AS ORIENTATION GROUP | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-3466922-A1 | CATALYST FOR CONVERTING ESTER TO AMIDE USING HYDROXYL GROUP AS ORIENTATION GROUP | Chubu University Educational Foundation (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-20130041000-A1 | NOVEL AZOLE COMPOUND | AJINOMOTO CO., INC. (JP) | 2013-02-14 | — | — | US | disclosed |
| WO-2010028193-A1 | COMPOUNDS INCLUDING PIMELIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2008009079-A2 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070690-A1 | CATALYST FOR CONVERTING ESTER TO AMIDE USING HYDROXYL GROUP AS ORIENTATION GROUP | EBP, NR1H3, APEH | POLB 2464/4885HDAC3 1162/4885HDAC1 1193/4885 |
| US-20130041000-A1 | NOVEL AZOLE COMPOUND | LPAR1, LPAR2, LPAR3 | POLB 4575/4885HDAC3 2281/4885HDAC1 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.